M-M-R II: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Live MMR virus vaccine

Indications/Uses

Simultaneous vaccination against measles, mumps & rubella in individuals ≥12 mth.

Click to view M-M-R II detailed prescribing information

Dosage/Direction for Use

0.5 mL IM/SC into the outer aspect of the upper arm. Recommended vaccination schedule Individual 1st vaccinated at ≥12 mth should be revaccinated at 4-6 yr or 11-12 yr. Measles outbreak schedule Infant vaccinated between 6-12 mth should receive 2nd dose at 15 mth, followed by revaccination at 4-6 yr or 11-12 yr.

Click to view M-M-R II detailed prescribing information

Overdosage

View M-M-R II overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity including gelatin. Anaphylactic or anaphylactoid reactions to neomycin. Febrile resp illness or other active febrile infection. Active untreated TB. Patients receiving immunosuppressive therapy. Blood dyscrasias, leukemia, lymphomas or other malignant neoplasms affecting bone marrow or lymphatic systems. Primary & acquired immunodeficiency states eg, AIDS or other clinical manifestations of HIV infection; cellular immune deficiencies; hypo- & dysgammaglobulinemic states. Severely immunocompromised individuals inadvertently vaccinated w/ measles-containing vaccine. Family history of congenital or hereditary immunodeficiency. Pregnancy; avoid pregnancy for 1 mth following vaccination.

Click to view M-M-R II detailed prescribing information

Special Precautions

Not to be inj IV. History of anaphylactic, anaphylactoid or other immediate reactions subsequent to egg ingestion. Patients w/ individual or family histories of convulsion, history of cerebral injury or other condition in which stress due to fever should be avoided. Current thrombocytopenia. Monitor temp elevation following vaccination. May result in temporary depression of tuberculin skin sensitivity. HIV-infected or immunosuppressed patients. Not to be given concurrently w/ Ig. Not recommended in concurrent use w/ DTP or oral poliovirus vaccines. Not to be used during pregnancy. Lactation. Infants <12 mth.

Click to view M-M-R II detailed prescribing information

Use In Pregnancy & Lactation

Click to view M-M-R II detailed prescribing information

Adverse Reactions

Inj site burning &/or stinging of short duration.

Drug Interactions

Interfered immune response w/ Ig. Defer vaccination for ≥3 mth following human Ig & blood or plasma transfusions.

Click to view M-M-R II detailed prescribing information

Storage

View M-M-R II storage conditions for details to ensure optimal shelf-life.

Description

View M-M-R II description for details of the chemical structure and excipients (inactive components).

Action

View M-M-R II mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.

Regulatory Classification

Presentation/Packing

Form

M-M-R II vaccine (inj) (single-dose vial)

Packing/Price

(single dose) 0.5 mL x 1's

M-M-R II

measles, mumps and rubella vaccine

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig Pharma